MedGenome Inc. services

Antibody discovery is an important component for early-stage research studies, diagnostics, and therapeutics. Hybridoma technology has been the forefront tool in generating monoclonal antibodies but is time consuming and costly. MedGenome’s proprietary HitMab platform now enables researchers to identify antigen-specific antibodies in less than 6 months’ time.